Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacovigilance in perspective.

R H Meyboom1, A C Egberts, F W Gribnau

  • 1Netherlands Pharmacovigilance Foundation LAREB,'s-Hertogenbosch.

Drug Safety
|December 28, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idiosyncratic reactions to valproate. Clinical risk patterns and mechanisms of toxicity.

The International journal of risk & safety in medicine·2013
Same author

Making the rheumatologist aware of patients' non-adherence does not improve medication adherence in patients with rheumatoid arthritis.

Scandinavian journal of rheumatology·2010
Same author

Pharmacotherapy of epilepsy: state of the art and developments.

Journal of clinical pharmacy and therapeutics·2009
Same author

The case for good pharmacovigilance practice.

Pharmacoepidemiology and drug safety·2008
Same author

Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.

Annals of the rheumatic diseases·2008
Same author

The spectrum and types of adverse side effects to biological immune modulators: a proposal for new classification.

Folia biologica·2007
Same journal

Availability and Communication of Risk Management Strategies for Pregnancy Category X Medicines across Australian Medicine Information Sources.

Drug safety·2026
Same journal

The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysis.

Drug safety·2026
Same journal

Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal Analysis.

Drug safety·2026
Same journal

Developing a Hierarchical Algorithm to Identify Pregnancies and Determine Gestational Age from Nationwide Linked Health Data in Taiwan.

Drug safety·2026
Same journal

Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis.

Drug safety·2026
Same journal

Analytic Misjudgment of Drug Safety Evidence and Causality: From the Prosecutor's Fallacy and Simpson's Paradox to Artificial Intelligence.

Drug safety·2026
See all related articles

Pharmacovigilance, the study of drug benefits and risks, is a crucial scientific discipline evolving beyond spontaneous reporting. Developing good practices ensures data integrity for informed pharmacotherapeutic decisions amid complex drug development changes.

Area of Science:

  • Pharmacology
  • Drug Safety
  • Regulatory Science

Background:

  • Pharmacovigilance has evolved from a minor regulatory appendix to a major activity.
  • Drug positioning and benefit-risk evaluation occur post-market with accumulated global data.
  • The field faces scientific, ethical, logistical, legal, financial, and commercial challenges.

Purpose of the Study:

  • To highlight pharmacovigilance as a scientific discipline integral to drug evaluation.
  • To emphasize the need for good pharmacovigilance practices for data integrity.
  • To underscore the proactive role of pharmacovigilance in monitoring evolving drug development systems.

Main Methods:

  • Review of the evolving role and scope of pharmacovigilance.
  • Analysis of the scientific, ethical, and logistical aspects of drug benefit-risk evaluation.

Related Experiment Videos

  • Discussion of the integration of pharmacovigilance into pharmacotherapeutic decision-making.
  • Main Results:

    • Pharmacovigilance is essential for evaluating marketed medicines, extending beyond spontaneous reporting.
    • Effective pharmacovigilance requires robust practices for data collection and utilization.
    • The discipline plays a critical role in individual and collective pharmacotherapeutic decisions.

    Conclusions:

    • Pharmacovigilance is a growing scientific discipline vital for drug safety and efficacy.
    • Proactive monitoring is necessary to address consequences of changes in drug development and regulation.
    • Good pharmacovigilance practices are fundamental for reliable drug benefit-risk assessment.